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The effect of adherent cells, prostaglandin E2 (PGE 2), 
and indomethacin on LAK cell activity of C57BL/6J (B6) mice 
was investigated. Depletion of adherent cells from 
splenocyte cultures prior to LAK cell generation increased 
LAK cell cytotoxicity by 60% compared to non-depleted 
splenocyte cultures. Depletion of adherent cells from 
splenocyte cultures following five days of incubation and 
prior to the LAK cell assay resulted in a similar 
enhancement. Indomethacin, an inhibitor of prostaglandin 
synthesis, enhanced LAK cell cytotoxicity in splenocyte 
cultures. PGE 2 inhibited LAK cell cytotoxicity of adherent 
cell depleted splenocytes 28% and 88% at l0-6 M and 10-sM. 
In vivo treatment of mice with indomethacin increased LAK 
cell cytotoxicity two fold compared to ethanol treated 
controls. LAK cell cytotoxicity was greatest in 
splenocytes from indomethacin treated mice cultured with 
additional indomethacin at 10.0 ug/ml. This study 




I would like to thank everyone who assisted in this 
research and in the preparation of this thesis. To the 
members of my committee for reviewing the manuscript and 
for their guidance during research and thesis preparation. 
To the editorial assistant, Candie Stewart, for assistance 
far beyond her job description. To my fellow graduate 
students, Sharareh Sazesh and Bonny Bass for their 
friendship and technical assistance. And especially, to my 
parents, for their support and encouragement and for always 
believing this could be done. 
iii 
TABLE OF CONTENTS 
LIST OF FIGURES ••••.•..••.•••••••• vi 
INTRODUCTION . . 1 
Characteristics of LAK cells • . ••••••• 2 
Stimulus for activation •••.••••••••. 3 
Target cell specifity • . • . . . • • . . 4 
Mechanism of lysis . • • • • . . • • • • . 5 
Phenotypes of effector and target cells .•••. 5 
Adoptive transfer of in vitro generated 
LAK cells in mice ••.•.••••••••••. 6 
Treatment of tumor-bearing mice with 
high dose IL-2 alone • • • • • • • • . • • • • 7 
Adoptive immunotherapy of human cancers 
with LAK cells and IL-2 •••..•.•..••• 8 
The role of prostaglandins in regulation of the 
immune response ••••••••....••••• 8 
Prostaglandins suppress NK activity ..• 9 
Prostaglandins suppress CTL activity 10 
In vivo treatment with indomethacin inhibits 
metastasis in tumor-bearing mice. • • • . • 11 
MATERIALS AND METHODS 
Animals • . • • . . • • • . • .•• 
Cell lines • • • . .••••••..•• 
Preparation of non-depleted splenocyte 
suspensions ..•••••••• 
Adherent cell depletion prior to LAK cell 
generation .••.•.••••.•••. 
RI L- 2 • • • • • • • • • • • • 
Generation of LAK cells ••••. 
Determination of cytotoxicity •••. 













RESULTS •• . . . . . . . . . . . . . . . . . . . . . 
Effect of RIL-2 concentration and culture 
period on LAK cell generation 
and cytotoxicity •.•••••••••••••• 
Enhancement of cytotoxicity by 
centrifugation •..•••••••• 
Effect of adherent cell depletion 
immediately prior to LAK cell assay •.•••• 
Effect of adherent cell depletion prior to 
culture or prior to assay on 
LAK cell cytotoxicity ••.•••.•••••• 
Effect of RIL-2 on cell number .•••••.•• 
Enhancement of LAK cell cytotoxicity by 
indomethacin •••••.•••.•.•••••• 
Effect of indomethacin addition immediately 
prior to assay on LAK cell cytotoxicity •••• 
Effect of PGE 2 on LAK cell cytotoxicity ••.• 
Effect of in vivo treatment of mice with 
indomethacin followed by in vitro culture 
with indomethacin •...•.••••••••• 
DISCUSSION . ~ . . . . . . . . . . . . . . . . . . . 

















LIST OF FIGURES 
Effect of RIL-2 concentration and culture 
period on growth of murine splenocytes . 
Effect of RIL-2 concentration and culture 
period on LAK cell cytotoxicity . . . . 
Enhancement of LAK cell cytotoxicity 
by centrifugation ...•••.•• 
. . 
. . 
4. Effect of adherent cell depletion immediately 
. . . 18 
. . . 19 
• . 21 
prior to assay on LAK cell cytotoxicity •..•. 22 
5. Effect of adherent cell depletion prior 
to culture or prior to assay on 
LAK cell cytotoxicity ••••.•..••••.• 24 
6. Effect of RIL-2 and adherent cell 
depletion on growth of murine splenocytes ..•. 25 
7. Enhancement of LAK cell cytotoxicity 
following culture with indomethacin 
8. Effect of indomethacin addition immediately 
• • • 2 6 
prior to assay on LAK cell cytotoxicity ..• 28 
9. Effect of PGE 2 on LAK cell cytotoxicity of 
adherent cell depleted splenocyte cultures .•.. 29 
10. Effect of PGE2 on LAK cell cytotoxicity of 
non-depleted splenocyte cultures •.••.••• 30 
11. Enhancement of LAK cell cytotoxicity by 
in vivo treatment with indomethacin 
followed by culture with additional 
indomethacin •••.••••••••.•••.•• 33 
vi 
INTRODUCTION 
Immunological approaches to cancer therapy have been 
the focus of study for the past two decades (1, 2). Early 
clinical treatment protocols were directed toward 
immunization against specific tumor cells and/or tumor 
associated antigens. These attempts to immunize patients 
were unsuccessful and have been abandoned due to the 
inability to stimulate sufficiently strong responses to 
putative tumor antigens. Efforts to establish general 
immune stimulation that would concomitantly increase an 
antitumor response were also unsuccessful due to the 
general immunoincompetence of the tumo~bearing host (1). 
Recent approaches in cancer therapy involve adoptive 
transfer of tumor specific cytotoxic cells (cytotoxic T 
lymphocytes) in an effort to mediate antitumor effects. 
This method has the advantage of not being restricted to 
immunocompetent recipients. Adoptive transfer of tumor 
specific cytotoxic cells is limited, however, because it is 
difficult to generate large numbers of these cells. 
Additionally, most tumors are weakly _antigenic or 
nonantigenic, which prevents generation of cytotoxic T 
lymphocytes (2, 3). 
Yron et al. (4) and Lotze et al. (5) were first to 
describe lymphocytes which, when cultured with the 
lymphokine interleukin-2 (IL-2), were capable of lysing 
fresh autologous tumor cells. These lymphokine-activated 
killer (LAK) cells can be generated in large numbers and 
are cytotoxic for many immunogenic and nonimmunogenic tumor 
cells. LAK cells thus have potential for the successful 
immunotherapy of cancer. 
Characteristics of LAK cells. LAK cells are distinct 
from two other cytotoxic effectors, natural killer (NK) 
cells and cytotoxic T lymphocytes (CTL) (3, 6-9). LAK 
cells can be generated in vitro by addition of IL-2 to 
cultures of fresh human peripheral blood lymphocytes (PBL) 
from healthy individuals or to PBL cultures from 
tumor-bearing patients. LAK cells can also be generated by 
incubation of IL-2 with splenocytes of both normal and 
tumor-bearing mice. 
The in vitro cytotoxicity of LAK cells directed 
against a variety of tumors has been extensively documented 
in both rodents and humans (5, 6, 9-14). LAK cells have 
been characterized as to the stimulus responsible for their 
activation, their target cell specificity, their mechanism 
of lysis, and the phenotypes of their precursor and 
effector cells. 
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Stimulus for activation. The only stimulus thus far 
shown to be required for generation of LAK cells is IL-2 
(5, 6, 9, 11, 15). Treatment of human PBL with monoclonal 
antibody against the IL-2 receptor prior to culture with 
the lymphokine blocked LAK cell activation (9, 16). 
Generation of LAK cells in the presence of IL-2 appears to 
be universal. Lymphocytes from all strains of mice thus 
far tested (6) and from both normal and tumor-bearing 
humans exhibited similar patterns of lysis after IL-2 
exposure (7-9). 
LAK cells are distinguished from other cytotoxic 
effectors by a requirement of only a single signal for 
activation. Classical CTLs require at least two, and 
possibly three, signals for activation: 1) antigen or 
mitogen, 2) IL-2, and 3) cytoxic cell differentiation 
factor, CCDF (13, 17, 18). Recently Yang et al. (18) have 
described the generation of a new class of cytotoxic 
effector cells, Lymphokine-Induced Cytotoxic Cells (LICC). 
These cells do not require stimulation with antigen or 
mitogen but differ from LAK cells in that both IL-2 and 
CCDF are required for stimulation. Classical NK effectors 
do not require activation (19). However, NK activity can 
be augmented by either interferon (20, 21) or IL-2 (22), 
resulting in a broadened target cell specificity against 
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fresh tumor cell lines, chemically modified cells, and 
virus infected cells (23). 
Target cell specificity. LAI< cells are specifically 
cytotoxic to a variety of fresh, noncultured, autologous, 
syngeneic or allogeneic primary and metastatic tumor cells. 
LAK cells lyse freshly isolated tumor cells that are 
resistant to lysis by NK cells. However, LAI< cell activity 
directed against fresh normal cells has not been reported 
(6-8). Additionally, all cultured cell lines thus far 
tested are susceptible to LAK cell mediated lysis (24). 
Thus, LAI< cell lysis is not limited by histocompatibility 
restrictions or by any currently conceivable antigenic 
molecular epitope (13). This broad spectrum of tumor lysis 
distinguishes LAK cells from conventional CTLs, which 
demonstrate antigen specificity (24), and classical NK 
cells, which lyse a limited number of tumors (23). 
Recent studies have supported the hypothesis that 
individual LAK cells are "polyspecific" and capable of 
lysing a variety of target cells (12, 13). A common 
determinant on tumor cells which is not present on normal 
PBL may be the recognition structure necessary for LAI< cell 
cytotoxicity. LAK cell mediated lysis of syngeneic 
concanavalin A (Con A)-induced lymphocyte blasts in the 
mouse (6), and of trinitrophenyl (TNP)-modified autologous 
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PBL in the human (13) indicate that LAK cells may operate 
via recognition of a form of "altered self" (13). 
Mechanism of lysis. LAK cell cytotoxicity occurs via 
a granule exocytosis mechanism similar to that of other 
cytotoxic effectors. Cytoplasmic granules of LAK cells 
contain a cytolysin that has identical properties to that 
of NK cells and CTLs (14). 
Phenotypes of effector and target cells. Distinctions 
between LAK cell precursors and effectors and those of CTLs 
or NK cells have been functionally demonstrated by a number 
of studies. These include: analysis of congenitally 
immunodeficient mice (24); pattern of precursor 
regeneration following gamma irradiation (19), bone marrow 
transplantation (25, 26), or sublethal dose of 
cyclophosphamide (27); bone marrow fractionation on Percoll 
discontinuous gradients (28); differential susceptibility 
to lysis of human oncogene-transfected tumor cells (29); 
tissue distribution (7); and requirement for proliferation 
( 7) • 
The phenotype of LAK cell precursors and effectors and 
their relation to surface markers commonly expressed by NK 
cells and CTLs remains controversial. Early attempts to 
characterize the murine LAK cell precursor for the presence 
of the T cell marker, Thy-1, resulted in mixed findings. 
Rosenstein et al. (6), and Merluzzi et al. (25}, 
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demonstrated the presence of Thy-1 on LAK cell precursors 
whereas Mule et al. did not (30, 31). Neither of these 
groups reported the existence of the NK marker, asialo 
GM-1, on the surface of LAK cell precursors. After 
activation with IL-2, however, Thy-1 and other T lymphocyte 
markers are consistently demonstrated on the surface of LAK 
effector cells (1, 6, 10, 25, 32-34). In humans, LAK cell 
precursors have T-cell and NK-cell markers, whereas the 
mature LAK effector cells have only T-cell markers (1, 30, 
34). However, the most recent reports indicate that LAK 
cell precursors and effectors of mice and humans express NK 
associated markers on their surfaces (23, 35). 
It has been proposed that there is not a single unique 
progenitor of LAK cell activity, but rather that multiple 
subsets of lymphocytes {predominantly NK cells) become 
cytotoxic in response to IL-2 (23). Alternatively, LAK 
cells may represent the expansion of a common point in the 
differentiation of CTLs and NK cells (16). 
Adoptive transfer of in vitro generated LAK cells in 
mice. Infusion of in vitro generated LAK cells and 
systemic administration of low doses of IL-2 mediates 
significant tumor reduction in mice. Tumors susceptible to 
LAK cell killing include established pulmonary (3, 31, 33, 
36, 37), and hepatic (38, 39) metastasis of varied 
histiological types. No significant reduction of tumor 
6 
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burden was accomplished using LAK cells alone. This 
reflects the absolute dependence of LAK cells on the 
continued presence of IL-2 (3, 5-9). In vivo proliferation 
of infused LAK cells is directly related to the dose of 
IL-2 administered {40, 41). Continuously administered low 
doses of IL-2 are most effective in maintaining the 
viability of LAK cells. The cytotoxic activity of these 
LAK cell effectors is enhanced compared to LAK cell 
effectors maintained with the same amount of IL-2 
administered in a single dose {42, 43). 
Treatment of tumor-bearing mice with high dose IL-2 
alone. High doses of IL-2 alone {25000 - 100000 U/mouse 
injected intraperitoneally 3 times daily) have been 
effective in the treatment of intradermal tumors, lung and 
liver metastasis, and disseminated leukemia in mice {34, 
38, 44). This treatment is thought to be mediated by the 
in vivo induction of LAK cells. This hypothesis is 
supported by the finding that the antitumor effects of IL-2 
are eliminated if mice receive sublethal irradiation. This 
implies that IL-2 is not directly mediating tumor regres-
sion but is acting through a radiosensitive host component 
{34, 38). It has also been suggested that high dose IL-2 
may mediate tumor eradication through the induction of 
lymphokine secretion {34, 44), or by augmentation of 
specific T cell immunity {44). These doses of IL-2 cause 
significant toxicity in mice, and limit the amount of 
recombinant IL-2 that can be administered (38). 
Adoptive immunotherapy of human cancers with LAK cells 
and recombinant IL-2. Animal models have been used to 
define parameters for adoptive immunotherapy of human 
cancers with LAK cells and recombinant IL-2 (RIL-2) 
(45-47). Objective regression of cancer has been noted in 
a number of patients maintained on these treatment proto-
cols (46). However, the high toxicity of RIL-2 has limited 
the potential uses of such therapy in humans (46, 47). 
The role of prostaglandins in regulation of the immune 
response. One class of compounds which has been shown to 
mediate killing by both CTLs and NK cells are the 
prostaglandins (48-56). Studies in animal models have 
demonstrated that prostaglandins of the E series (PGEs) 
modulate many immune responses (57-60). These include T 
lymphocyte proliferation (57, 58) and the production and 
secretion of IL-2 (59, 60). PGEs also inhibit human blood 
mononuclear cell proliferation by interfering with the 
production of IL-2 and with IL-2 independent proliferation 
(61-63). IL-2 receptor expression is not affected by 
treatment with PGEs (64). Walker et al. (63) reported that 
PGE 2 inhibited the IL-2 dependent cell cycle event which is 
required for T cell proliferation. Prostaglandin E2 
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primarily exerts its inhibitory effect on lymphocyte pro-
liferation through an inhibition of IL-2 production (63). 
A population of glass-adherent mononuclear cells 
suppresses T-cell mitogenic activity through production of 
PGEs (57). These findings suggest that PGEs may serve as 
endogenous modulators of human immune reactions. Removal 
of glass-adherent cells from mononuclear populations 
results in increased IL-2 production by nonadherent cells. 
Most of the particulate and soluble agents known to 
stimulate macrophages result in increased production of 
PGEs (58). This is consistent with the earlier finding 
that macrophages synthesize and release prostaglandins in 
response to inflammatory stimuli (65). Thus, PGE2 secreted 
by macrophages may serve to regulate the production of IL-2 
under physiological conditions (61). 
Prostaglandins suppress NK activity. Addition of PGEs 
to murine NK cell assays results in marked and dose-
dependent suppression of cytotoxicity (48, 53). Maximal 
suppression of cytotoxicity occurred when PGEs were present 
throughout the entire assay period. This indicates that 
PGEs act at the effector level in mediating inhibition of 
NK cell function. After treatment with indomethacin or 
aspirin, compounds which block PGE production, NK cell 
activity is restored to normal or near normal levels in 
tumor-bearing animals. Thus, PGEs are potent inhibitors of 
9 
NK cell activity in vitro and, under certain conditions, 
PGEs may inhibit NK cell activity in vivo {48). 
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In humans, NK cellular cytotoxicity can be activated 
or inhibited by PGE2 {50). T cells may not be involved in 
the control of PGE2 production. Their presence is 
necessary, however, for PGE2 mediated inhibition of NK cell 
activity { 56). 
Prostaglandins suppress CTL activity. PGE 2 suppresses 
CTL activity {49, 51, 52, 54, 55). Wolf and Droege {55) 
have shown that endogenously produced PGE inhibits the 
production of IL-2. However, the addition of exogenous PGE2 
to CTL cultures also inhibits cytotoxicity in a dose-
dependent manner. These results support the hypothesis 
that PGE 2 directly inhibits CTL responses. 
The mechanism of inhibition by PGEs seems to be via an 
increase in intracellular levels of 3', 5' cyclic adenosine 
monophosphate {cAMP) {51, 52, 54). The modulating effects 
of the intracellular levels of cAMP upon the attacking cell 
population are dependent upon the concentration of this 
cyclic nucleotide at the moment of initial interaction with 
the target cells {54). Agents that increase cAMP levels, 
including PGEs, inhibit the activity of in vivo-generated 
CTLse These agents have little inhibitory effect on the 
activity of in vitro-generated CTLs. It has been suggested 
that culture induces nonspecific desensitization to cyclic 
AMP-active agents (52). 
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In vivo treatment with indomethacin inhibits 
metastasis in tumor-bearing mice. In vivo treatment of 
tumor-bearing mice with indomethacin causes a reduction in 
tumor metastasis (66-68). The mechanism of indomethacin 
mediated inhibition of tumor growth has been proposed to be 
via reversal of immunosuppression caused by endogenously 
produced prostaglandins (66). Alternatively, indomethacin 
may block PGE mediated inhibition of NK cell activity (68). 
The effects of indomethacin on LAK cell activity in mice 
have not been reported. 
The purpose of the research presented here is to 
characterize the regulatory effects of adherent cells, 
PGE 2 , and indomethacin on the murine lymphokine activated 
killer cell. Additionally, this report describes methods 
which significantly enhance the cytotoxic response of 
murine LAK cells. 
MATERIALS AND METHODS 
Animals. C57BL/6J (B6) mice were obtained from 
Jackson Laboratories, Bar Harbor, Maine. Experiments were 
performed with male mice, 6 to 10 weeks of age. 
Cell lines. P815 mastocytoma cells (69, 70) were 
maintained in culture by in vitro passage in Dulbecco's 
Modified Eagle medium (GIBCO, Grand Island, NY) sup-
plemented with 10% v/v heat-inactivated fetal calf serum 
(FCS), 100 U/ml penicillin, 100 ug/ml streptomycin, 60 
ug/ml 1-glutamine, and 5 x l0-3 M 2-mercaptoethanol. 
Preparation of non-depleted splenocyte suspensions. 
Pooled whole splenocyte suspensions (non-depleted 
splenocytes) were prepared in a manner similar to the 
method of Merluzzi et al. (10). The spleens of 2 to 6 
animals were aseptically removed and disassociated in 
supplemented RPMI-1640 medium (GIBCO) using a sterile 
syringe plunger. The resulting single-cell suspension was 
incubated at 0°C for 5 min to allow large debris to settle. 
The cells remaining in the supernatant were removed and 
washed once with RPMI-1640 medium. Viable cell counts were 
determined by trypan blue exclusion and cells were adjusted 
to the appropriate concentration in RPMI-1640 medium. 
12 
13 
Adherent cell depletion prior to LAK cell generation. 
Adherent cell depleted splenocyte cultures were prepared by 
adjusting non-depleted splenocyte suspensions to a 
concentration of 2 x 106 cells/ml. Aliquots of 15-20 ml 
were added to 100 x 20 mm plastic tissue culture dishes 
(Falcon, Becton Dickinson, Oxnard, CA) and incubated for 1 
hr at 37°C in a 5% CO2- 95% air atmosphere. Following 
incubation the plates were washed vigorously with warm 
RPMI-1640 medium to remove non-adherent cells. 
RIL-2. A recombinant DNA preparation of human IL-2 
cloned in Escherichia coli was provided by the Cetus 
Corporation (Emeryville, CA) (15). Units of IL-2 were 
calculated from the total specific activity reported by the 
manufacturer. Activity was verified using the IL-2 
dependent cell line HT-2 (71) and the standard microassay 
(72). One unit of activity is defined as the reciprocal of 
the dilution which results in one-half of the maximal 
proliferation of HT-2 cells (71, 72). 
Generation of LAK cells. LAK Cells were generated by 
culturing non-depleted or adherent cell depleted 
splenocytes in 25-cm2 tissue culture flasks (Corning 
Glassware, Corning, NY) containing 5-10 ml of RPMI-1640 
medium. The final concentration of responders was adjusted 
to 5 x 106 /ml. RIL-2 was added to these cells at a final 
concentration of 1000 U/ml, the optimal concentration 
determined for generation of LAK cell cytotoxicity. 
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Culture flasks were incubated upright for 5-8 days at 37°c 
in 5% C02-95% air atmosphere. After incubation, LAK cells 
were removed from the flasks and were used for in vitro 
cytotoxicity studies. Adherent cell-depleted LAK cell 
suspensions were obtained by removal of the flask contents 
only. Whole spleen (non-depleted) LAK cell suspensions 
were obtained as follows. Flask contents were removed as 
described above. Five ml of RPMI-1640 medium at 4°C was 
added to the flask and the flask was incubated at 0°C for 2 
hr. The contents were then combined with that of the 
original flask. This low-temperature incubation allowed 
recovery of cells which had adhered to the plastic surface 
of the tissue culture flask during LAK cell generation. 
Determination of cytotoxicity. A standard chromium-
release assay was performed to determine LAK cell activity 
(10). Briefly, 100 uCi of ~Cr (New England Nuclear, 
Boston, MA) was added to a pellet of 8-10 x 106 P815 tumor 
cells and incubated for 2 hr in a 37 C water bath. Cells 
were washed three times in Dulbecco's medium, and 100 ul 
containing 5 x 104 cells was added to 12 x 75 mm sterile 
test tubes (Fisher Scientific Products). LAK cells were 
harvested, washed once in RPMI-1640 medium, and added to 
each of three tubes to produce 100:1, 50:1, and 25:1 
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effector (LAK) :target (P815) cell ratios. The cultures 
were mixed with a MLA pipette, centrifuged for 3 min at 30 
x g, and incubated at 37°C for 4 hr in a humidified 
atmosphere with 5% CO2- 95% air. Following incubation, the 
tubes were recentrifuged at 400 x g for 5 min to pellet 
cells. The amount of radioactivity released into 0.150 ml 
of the supernatant of each culture was determined in a 
gamma counter. Spontaneous release controls were obtained 
from supernatants of target cells incubated in medium 
alone. Maximum release controls were determined from 
cultures in which target cells were incubated with a 1% v/v 
solution of NONIDET P40 detergent (Bethesda Resear9h 
Laboratories, Rockville, MD). The percentage 51cr release 
was determined from the following formula: 
Experimental Release - Spontaneous Release 
X 100 % 
Maximum Release - Spontaneous Release 
Prostaglandin and indomethacin. Prostaglandin E2 
(PGE2) and indomethacin were purchased from Sigma Chemical 
Co., St. Louis, MO. PGE2 was dissolved in absolute ethanol 
to a concentration of 2 x l0-3M, and stored at -20°C. This 
stock solution was later diluted in RPMI-1640 medium and 
added to cultures at concentrations of 10
7 
to l0- 5 M. 
Controls containing equivalent concentrations of ethanol 
were included for each dilution of PGE2 tested. 
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In the in vitro studies, indomethacin was dissolved in 
absolute ethanol at a concentration of 10 mg/ml and diluted 
to the appropriate concentrations with RPMI-1640 (see 
Results section for concentrations used). In the in vivo 
studies, groups of mice were provided with 14 ug/ml 
indomethacin in 0.16% ethanol ad libitum in drinking water 
for 21 days. The drinking water was changed twice weekly. 
Control animals received ethanol in their drinking water at 
a concentration equivalent to that present in the 
indomethacin preparations. 
Statistics. Statistical differences in responses to 
various treatment protocols were determined by chi-square 
analysis. 
RESULTS 
Effect of RIL-2 concentration and culture period on 
LAK cell generation and cytotoxicity. Whole splenocytes 
(1.5 x 10 7 ) obtained from a single animal were incubated in 
the presence of RIL-2 for 3 or 5 days. Total viable cell 
counts were determined and cytotoxic ~ctivity was measured 
for duplicate cultures at 100:1 effector:target (E:T) cell 
ratios. At all RIL-2 concentrations, cell recovery was 
consistently less than 100%. Chi square analysis 
determined that no significant difference {p = 0.80) exists 
between the number of cells recovered at varying RIL-2 
concentrations and culture periods (Fig. 1). 
Cytotoxicity increased with increasing incubation time 
at all concentrations of RIL-2 tested (Fig. 2). Cell 
numbers were similar after both time periods (Fig. 1). 
Greatest LAK cell cytotoxicity was generated following 5 
days incubation (Fig. 2). 
Enhancement of cytotoxicity by centrifugation. 
Effectors and radiolabeled target (P815) cells were 
combined and centrifuged at 30 x g for 3 min prior to LAK 
17 
Figure 1. Effect of RIL-2 concentration and culture 































































Figure 2. Effect of RIL-2 concentration and culture 
























































cell assay. Centrifugation enhanced LAK cell cytotoxicity 
at higher concentrations of RIL-2 (>125 U/ml) (Fig. 3). 
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Effect of adherent cell depletion immediately prior to 
LAK cell assay. Splenocytes were cultured with RIL-2 for 5 
days. Following incubation, adherent cell depleted and 
non-depleted splenocyte cultures were assayed for LAK cell 
cytotoxicity. Higher concentrations of RIL-2 (>125 U/ml) 
enhanced LAK cell cytotoxicity of both cell types assayed 
in a dose-dependent manner. The median enhancement of 
cytotoxicity of adherent cell depleted cultures was 60% 
compared to non-depleted cultures. Highest LAK cell 
cytotoxicity occurred with 1000 U/ml RIL-2 at 50:1 and 
100:1 E:T ratios (Fig. 4). 
Effect of adherent cell depletion prior to culture or 
prior to assay on LAK cell cytotoxicity. Adherent cell 
depleted (-ADH/CULTURE) and non-depleted splenocytes were 
cultured with 1,000 U/ml RIL-2 for 5 and 8 days. Some LAK 
cells generated from the non-depleted splenocyte cultures 
were depleted of adherent cells prior to the assay 
(-ADH/ASSAY). Cytotoxicity increased in all adherent cell 
depleted cultures compared to non-depleted cultures at each 
E:T ratio tested. The mean percent enhancement was 29.7% 
for suspensions depleted of adherent cells prior to assay 
and 40.5% for those depleted prior to culture (5 day 
incubation)~ Following 8 day culture, the mean percent 
Figure 3. Enhancement of LAK cell cytotoxicity by 
centrifugation. 



















































































































































Figure 4. Effect of adherent cell depletion 
immediately prior to assay on LAK cell cytotoxicity. 
Non-depleted preparations contain both adherent and 
nonadherent cells. "ADH DEPLETED" indicates depletion of 
adherent cells immediately prior to assay (after culture 
with RIL-2). 
















































































































































































enhancement was 124% in cultures depleted of adherent cells 
prior to assay and 119% in those depleted prior to culture 
(Fig. 5). Adherent cell depletion, either before or after 
culture with RIL-2 resulted in a significant enhancement in 
cytotoxicity compared to non-depleted splenocytes (p = 
<0.005 for depletion prior to or following LAK cell 
generation). 
Effect of RIL-2 on cell number. RIL-2 added to 
splenocyte cultures increased cell numbers compared to 
splenocytes cultured without RIL-2. The highest number of 
cells was recovered from adherent cell depleted splenocytes 
cultured with RIL-2 for 8 days (Fig. 6). 
Enhancement of LAK cell cytotoxicity by indomethacin. 
Splenocytes were cultured with RIL-2 and indomethacin, an 
inhibitor of prostaglandin synthesis. Controls consisted 
of splenocyte cultures with RIL-2 plus medium (MEDIUM) or 
ethanol (EtOH). Splenocytes were collected after 5 days 
incubation and LAK cell cytotoxicity was determined. 
Indomethacin at concentrations greater than 2.5 ug/ml 
enhanced LAK cell cytoxicity compared to ethanol and medium 
controls (Fig. 7). 
Effect of indomethacin addition immediately prior to 
assay on LAK cell cytotoxicity. Adherent cell depleted and 
non-depleted splenocytes were cultured with RIL-2 for 5 
days. Some non-depleted splenocyte· cultures were depleted 
Figure 5. Effect of adherent cell depletion prior to 
culture or prior to assay on LAK cell cytotoxicity. 
Non-depleted preparations contain both adherent and 
nonadherent cells. "-ADH/ASSAY" indicates adherent cell 
depletion on the surface of plastic tissue culture flasks 
prior to assay and following culture with RIL-2. 
"-ADH/CULTURE" indicates adherent cell depletion on plastic 










































































































































































































Figure 6. Effect of RIL-2 and adherent cell depletion 









































































































Figure 7. Enhancement of LAK cell cytotoxicity 
following culture with indomethacin. Medium control 
(MEDIUM) consisted of splenocytes cultured with RIL-2 and 
RPMI-1640 medium only. Ethanol control (EtOH) consisted of 
splenocytes cultured with RIL-2 and RPMI-1640 medium plus 
100% ethanol at concentrations equivalent to those present 
in indomethacin supplemented cultures. 
















































































































of adherent cells before assay. Indomethacin was added to 
effector/target combinations immediately prior to LAK cell 
assay. Indomethacin did not significantly affect cytotoxic 
activity of any cell population at the concentrations 
tested (p-values = 0.50 for non-depleted splenocytes, 0.70 
for adherent cell depletion prior to assay, and 0.30 for 
adherent cell depletion prior to culture} (Fig. 8) .• 
Effect of PGE2 on LAK cell cytotoxicity. Higher 
concentrations of PGE2 inhibited LAK cell cytotoxicity of 
adherent cell depleted splenocyte cultures. This 
inhibition was 28% and 88% at l0-6M and 10-sM, 
respectively, compared to the appropriate alcohol controls 
(mean of 2 separate experiments} (Fig. 9}. Prostaglandin E2 
suppressed LAK cell cytotoxicity of non-depleted spleno-
cytes from the same animals at the highest concentration 
(l0- 5M} tested (Fig. 10}. 
Effect of in vivo treatment of mice with indomethacin 
followed by in vitro culture of non-depleted splenocytes 
with indomethacin. Mice were treated with indomethacin or 
an equivalent concentration of ethanol in drinking water 
for 21 days. Prior to culture with RIL-2, indomethacin 
treated mice had elevated splenocyte counts compared to 
ethanol treated controls. Cell numbers were not 
significantly different for the treated or untreated groups 
following 5 days of culture (p=.90} (Table I}· 
Figure 8. Effect of indomethacin addition immediately 
prior to assay on LAK cell cytotoxicity. Legend is in 
Fig. 5. 
































































































































Figure 9. Effect of PGE2 on LAK cell cytotoxicity of 
adherent cell depleted splenocyte cultures. "MEDIUM" 
consisted of splenocytes cultured with RIL-2 and RPMI-1640 
medium only. "EtOH" consisted of splenocytes cultured with 
RIL-2 and RPMI-1640 medium plus 100% ethanol at 


























































































Figure 10. Effect of PGE2 on LAK cell cytotoxicity of 
non-depleted splenocyte cultures. No IL-2 control (NO 
IL-2) consisted of splenocytes cultured with RPMI-1640 
medium only. "MEDIUM" consisted of splenocytes cultured 
with RIL-2 and RPMI-1640 medium. "EtOH" consisted of 
splenocytes cultured with RtL-2 and RPMI-1640 medium plus 
100% ethanol at concentrations equivalent to those present 












































































































EFFECT OF IN VIVO TREATMENT WITH INDOMETHACIN 
ON SPLEEN CELL NUMBER AND LAK CELL GENERATION 








Treated c 9.2 8.9 
Ethanol 
Controls d 6.5 9.8 
a Pooled spleen cell suspensions from 5 mice in each 
treatment group. 
bidentical cell ~umbers (2.5 x 10 7) cultured in the 
presence of 1000 U/ml RIL-2 for 5 days, washed once 
with supplemented RPMI-1640 medium, and enumerated. 
cAnimals maintained on 14 ug/ml indomethacin in drinking 
water for 21 days. 
d A . 1 . . d . 1 t t f th 1 nima s maintaine on eguiva en amoun so e ano 
in drinking water for 21 days. 
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LAK cells were generated from indomethacin treated or 
alcohol treated animals. Indomethacin was added to some 
splenocyte cultures from both treatment groups. 
Indomethacin treatment of mice increased LAK cell 
cytotoxicity compared to that of alcohol treated controls. 
The highest cytotoxicity was expressed by splenocytes from 
indomethacin treated mice cultured with additional 
indomethacin at 10.0 ug/ml (Fig. 11). 
32 . 
Figure 11. Enhancement of LAK cell cytotoxicity by 
in vivo treatment with indomethacin followed by culture 
with additional indomethacin. Ethanol treatment indicates 
animals treated with ethanol in drinking water at a 
concentration equivalent to that used in indomethacin 
treatment. 






























































































































Various culture methods have been used by different 
investigators for generation of LAK cells and assay of 
their cytotoxic activity (4, 7, 10, 13, 16). At present, 
no standard protocol for LAK cell generation and/or assay 
exists. This study identifies parameters which directly 
affect LAK cell analysis. The most important of these 
include centrifugation of effector/target cell combinations 
and removal of adherent cells. 
Low speed centrifugation of effector/target 
combinations greatly enhanced cytotoxicity in this study. 
Cytotoxicity is probably enhanced due to an increase in 
effector and target cell contact necessary for lysis. Some 
investigators have also incorporated a centrifugation step 
into their LAK cell assay (7-10, 35). 
LAK cell precursors and effectors are nonadherent 
(6, 8, 35), however, many investigators do not report the 
routine depletion of adherent cells prior to murine LAK 
cell assay or adoptive immunotherapy (12, 19, 44-46). This 
study demonstrates a significant enhancement in murine LAK 
cell cytotoxicity if adherent cells are depleted either 
34 
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before or after culture with RIL-2. This emphasizes the 
importance of adherent cell depletion in the preparation of 
LAK cells for in vitro studies or immunotherapy. This 
finding is consistant with recent reports of a similar 
suppressive action of adherent cells on human LAK cell 
generation (11, 73). 
Adherent cell depleted cultures, which show maximum 
LAK cell cytotoxicity, probably contain a higher proportion 
of LAK cells compared to non-depleted cultures. However, 
this higher proportion of LAK cells cannot fully account 
for the enhancement of cytotoxicity shown here. At the 
lowest E:T ratio tested, adherent cell depleted splenocytes 
demonstrated increased cytotoxicity compared to the highest 
E:T ratios of non-depleted splenocytes. Even when the 
number of non-depleted effector cells is increased 4-fold 
(from 25:1 to 100:1 E:T ratios), adherent cell depleted 
cultures continue to express higher levels of cytotoxicity. 
This explanation does not rule out the possibility 
that adherent cell depletion increases LAK cell 
cytotoxicity on a per cell basis. Limiting dilution 
experiments and development of a method to enumerate LAK 
cells would serve to determine whether this is the case. 
The data in the present study showed that optimal LAK 
cell cytotoxicity was generated following 5 days culture 
with 1000 U/ml RIL-2. Total viable cell numbers recovered 
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were similar for all RIL-2 concentrations tested and both 3 
and 5 day incubation periods. Viable cell recovery after 
culture with RIL-2 was consistently less than 100%. This 
is probably due to loss of non-RIL-2 responsive cells 
during the culture period. Measurable cytotoxicity was 
evident only in cultures incubated for 5 days at RIL-2 
concentrations routinely used by others (<1000 U/ml) 
(3, 10, 13, 14, 19, 25, 26, 28-32, 36-39). These results 
suggest that while cell recovery remains relatively 
constant, the proportion of LAK cells continues to increase 
with increasing culture period. Increasing the amount of 
RIL-2 in splenocyte cultures 10-fold, increased 
cytotoxicity at both culture periods. However, lower 
concentrations were routinely used since quantities of 
RIL-2 available for this study were limited. 
The enhancement of LAK cell cytotoxicity following 
culture with indomethacin, an inhibitor of prostaglandin 
synthesis, is indirect evidence that products of the 
cyclooxygenase pathway modulate LAK cell activity. Darrow 
and Tamar (49) reported that indomethacin enhanced the 
proliferation and induction of cytotoxicity of CTLs 
generated from mixed lymphocyte cultures. They further 
reported that indomethacin had no effect if added just 
prior to the chromium release assay. These results may be 
directly related to those of the present study in which 
indomethacin had no effect when added immediately prior to 
the LAK cell assay. 
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Prostaglandins of the E series suppress cytotoxic 
activity of NK cells and CTLs in vitro at concentrations 
greater than l0-7 M (48, 49, 52, 59). Suppression of LAI< 
cell cytotoxicity by direct addition of prostaglandin has 
not been reported to date. This study describes inhibition 
of LAK cell cytotoxicity when PGE 2 is added to adherent 
cell depleted cultures at similiar concentrations. The low 
cytotoxic response observed at the highest concentration of 
PGE2 tested (l0-5 M) may be due to direct toxic effects of 
this compound on the LAK cell effectors themselves. 
Prostaglandin E2 was less effective on the inhibition of 
LAK cell cytotoxicity of non-depleted splenocytes. This 
may indicate that endogenous levels of PGs necessitate the 
addition of higher levels of exogenous PGE 2 to mediate the 
same inhibition. 
Parhar and Lala (67) have recently described 
regression of metastasis after in vivo trea~ment of mice 
with indomethacin and RIL-2. This combination therapy also 
increased in vitro cytotoxicity directed against various 
tumor targets. The studies presented here indicate that in 
vivo treatment with indomethacin alone was sufficient to 
increase in vitro LAK cell cytotoxicity. Cytotoxicity 
could be further enhanced by culturing splenocytes from 
indomethacin treated mice with additional indomethacin. 
This represents a new method for maximizing LAK cell 
cytotoxicity by a combination of in vivo and in vitro 
treatment with indomethacin. 
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The standard protocol for human adoptive immunotherapy 
includes infusion of in vitro generated autologous LAK 
cells and relatively high doses of RIL-2 {46). This 
approach is limited due to the toxicity of the RIL-2, and 
not the LAK cells themselves {46, 47). A pharmacological 
.agent that would reduce RIL-2 toxicity without eliminating 
its clinical benefit would increase the application of this 
type of immunotherapy. 
Indomethacin increased LAI< cell cytotoxicity without 
observable side effects at the concentration used in this 
study for in vivo treatment. Although it has not been 
tested, it is quite possible that indomethacin might also 
alleviate the adverse side effects of RIL-2 through its 
reported anti-inflammatory properties {74). 
Higher doses of indomethacin have been associated with 
a variety of adverse reactions in humans including 
gastrointestinal complications and bone marrow depression 
resulting in anemia and leukopenia {74, 75). During this 
study, in vivo indomethacin treated animals were examined 
daily and found to be healthy with no evidence of 
gastrointestinal complications, hair or weight los3. 
Hematological depression was not observed in this study. 
These results suggest that treatment of humans with low 
doses of indomethacin might increase LAK cell cytotoxicity 
and reduce RIL-2 toxicity. Further studies will have to be 
undertaken to determine: (1) if in vivo treatment with both 
RIL-2 and indomethacin would increase LAK cell cytotoxicity 
and reduce IL-2 toxicity in mice, and (2) if similar levels 
of indomethacin could be safely achieved in humans before 
such treatment is attempted. 
The studies presented here identify important 
parameters for LAK cell generation and assay. 
Additionally, these data indicate that adherent cells 
inhibit LAK cell cytotoxicity through production of 
prostaglandins and that these effects can be reversed by 
treatment with indomethacin. 
39 
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